“Multi-particulate dosage forms have several therapeutic and technological advantages over single-unit dosage forms, they can distribute evenly in the gastrointestinal tract, resulting in fewer adverse effects.” – Martínez-Terán et al. Pediatr Ther. 2017; 7:314
Even the best medications can have negative effects that affect a patient’s quality of life. However, your drug product’s format can positively affect the adverse event profile decreasing adverse events.
A common cause of adverse events is dose dumping: the premature release of a formulation’s active ingredient causing too much medication to be metabolized too quickly. Dose dumping can lead to dangerous adverse events. Multiparticulate drug delivery systems can lead to decreased dose dumping by encapsulating the active drug product in multiple small beads. In a 2008 review article, Dey et al. wrote, “multiparticulate drug delivery systems are especially suitable for achieving controlled or delayed release oral formulations with low risk of dose dumping, flexibility of blending to attain different release patterns as well as reproducible and short gastric residence time.” A 2012 research article also lists “reduced adverse effects and improved tolerability” as an advantage of multiparticulate drug delivery systems.
Compared to other medication formulations, such as coated tablets, multiparticulate drugs can lead to reduced adverse events caused by dose dumping. Orbis Biosciences® uses Precision Particle FabricationTM technology to develop format-flexible medications. With this microsphere technology, Orbis can develop format-flexible medications to meet your Target Product Profile criteria.